Navigation Links
UT Southwestern testing new hybrid hearing device combining advantages of hearing aids, implants
Date:4/17/2008

DALLAS April 17, 2008 A new hybrid hearing aid/cochlear implant device designed for patients who can benefit from both is being evaluated by UT Southwestern Medical Center otolaryngologists, as part of a multisite, national study.

The cross-breed device, called the DUET Electric-Acoustic System, or EAS, is already used in Europe, but not yet approved for use in the U.S. It targets a population currently falling through the cracks borderline cases for which hearing aids dont adequately distinguish sounds, but for who some natural hearing remains. For these individuals, cochlear implants that entirely replace natural hearing arent recommended either.

Hearing aids are typically worn on the outside of the ear by people who still have some natural hearing. Cochlear implants are surgically implanted into the ear and pick up lost middle- and higher-frequency sounds. They replace lost natural hearing by digitizing electrical impulses sent to the brain via wires implanted in the ear. The brain then interprets that as sound.

Most people with hearing difficulties have one or the other device, but not both.

Initial studies on the hybrid device suggest there is a synergistic effect achieved by maintaining the natural hearing and coupling it with the cochlear implant, particularly for distinguishing speech in noisy environments. The device both amplifies low frequencies and electronically stimulates middle and high frequencies.

The implant is specifically designed with a thin electrode to occupy less space in the inner ear. It is implanted by special surgical techniques to preserve natural hearing.

What patients can hope to get from the investigational device is a significant improvement in the ability to understand speech, especially in a noisy situation, said Dr. Peter Roland, chairman of otolaryngology-head and neck surgery at UT Southwestern.

The device is made by MED-EL Corp., which conducts the initial patient screening for the trial. The device is still investigational, so all of the potential risks are not known, Dr. Roland said. The most common serious complication is loss of what hearing is left in the ear that receives the implant. The opposite ear is unaffected. Significant hearing loss has occurred in 10 percent to 15 percent of recipients to date.

UT Southwestern is among about a dozen sites participating in the national trial. UT Southwestern researchers are seeking about a dozen participants, said Dr. Roland.

Potential study participants must be at least 18 years old, have moderate sloping to severe profound hearing loss, and have had minimal results from traditional hearing aids. Patients appropriate for the study will still have some natural hearing left but find themselves struggling to understand loud speech, particularly in noisy, crowded situations, even while wearing high-quality hearing aids. The target patient has hearing loss in high frequencies, but also requires a hearing aid to boost low-frequency sound.

We need people who are not getting enough benefit from their hearing aids to live normal lives, but who are not quite deaf enough for a regular cochlear implant, explained Dr. Roland.


'/>"/>

Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
2. UT Southwestern surgeons complete North Texas first single-incision gallbladder removal
3. UT Southwestern plastic surgeons deploy new carbon dioxide-based fractional laser
4. BMI criteria for obesity surgery should be lowered, UT Southwestern researchers suggest
5. UT Southwestern: Patients with mild Cushing syndrome may benefit from adrenalectomy
6. Physicians seek to improve the quality of sleep in ICU, researchers at UT Southwestern report
7. UT Southwestern urologist uses Botox to treat debilitating condition
8. UT Southwestern researcher named Howard Hughes Medical Institute investigator
9. 2 UT Southwestern researchers elected to National Academy of Sciences Institute of Medicine
10. UT Southwestern investigating hypothermic technique in treating pediatric head injuries
11. UT Southwestern scientist receives NIH Directors New Innovator Award
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UT Southwestern testing new hybrid hearing device combining advantages of hearing aids, implants
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for ... Island Park on Sunday, with sunny skies, a light breeze and temperatures in the ... , The 5k Run and Walk and 1-mile walk were held to ...
(Date:4/29/2016)... ... 2016 , ... The Wharton School of the University ... of the 2016 Wharton Business Plan Competition —as well as the Wharton ... the Committee Award for Most ‘Wow Factor,’ making them the first team in ...
(Date:4/29/2016)... Tarzana, CA (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type ... is to blame for the majority of skin cancer deaths. More than 10,000 people are ... average age at diagnosis is 62, it is the one of the most commonly diagnosed ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... , April 29, 2016 ... H1 2016" market research report that provides an ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ... also reviews key players involved in the therapeutic ...
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s announced ... the company,s valve repair and stent business, healthcare ... places Abbott more firmly into patient monitoring.  Kalorama ... fastest growing device areas, with double-digit growth expected ... report,  Advanced Remote Patient Monitoring . ...
Breaking Medicine Technology: